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Background: The C34T genetic polymorphism (rs17602729) in the AMPD1 gene, encoding the skeletal muscle-specific
isoform of adenosine monophosphate deaminase (AMPD1), is a common polymorphism among Caucasians that can
impair exercise capacity. The aim of the present study was twofold: (1) to determine the C34T AMPD1 allele/genotype
frequency distributions in Lithuanian athletes (n = 204, stratified into three groups: endurance, sprint/power and mixed)
and compare them with the allele/genotype frequency distributions in randomly selected healthy Lithuanian
non-athletes (n = 260) and (2) to compare common anthropometric measurements and physical performance
phenotypes between the three groups of athletes depending on their AMPD1 genotype.
Results: The results of our study indicate that the frequency of the AMPD1 TT genotype was 2.4% in the control
group, while it was absent in the athlete group. There were significantly more sprint/power-orientated athletes with
the CC genotype (86.3%) compared with the endurance-orientated athletes (72.9%), mixed athletes (67.1%),
and controls (74.2%). We determined that the AMPD1 C34T polymorphism is not associated with aerobic muscle
performance phenotype (VO2max). For CC genotype the short-term explosive muscle power value (based on Vertical
Jump test) of athletes from the sprint/power group was significantly higher than that of the endurance group athletes
(P < 0.05). The AMPD1 CC genotype is associated with anaerobic performance (Vertical Jump).
Conclusions: The AMPD1 C allele may help athletes to attain elite status in sprint/power-oriented sports, and the T allele
is a factor unfavourable for athletics in sprint/power-oriented sports categories. Hence, the AMPD1 C allele can be
regarded as a marker associated with the physical performance of sprint and power. Replications studies are required to
confirm this association.
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Physical performance is complex and includes the inter-
action of genetic and environmental factors. With the
rapid development of molecular research in sport, mul-
tiple genetic markers associated with physical perform-
ance have been discovered (among them are: ACE,
ACTN3, AMPD1, ADRB2, GDF-8, NOS3, PPARGC1A,
PPARA, HIF1, MtDNA markers, etc.) [1-3]. It should be
however emphasised that, besides ACTN3 [4], most
sports genetics studies have not yet been replicated in
independent samples.* Correspondence: valentina.gineviciene@gmail.com
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article, unless otherwise stated.Adenosine monophosphate deaminase (AMPD) is a
very important regulator of muscle energy metabolism
during exercise [5-7]. AMPD displaces the equilib-
rium of the myokinase reaction toward ATP production
(2 ADP ↔ ATP + AMP) by converting AMP to inosine
monophosphate (IMP) [5-9]. Moreover, the AMPD reac-
tion is the initial reaction of the purine nucleotide cycle
and plays a central role in the salvage of adenine nucleo-
tides as well as the determination of energy charge [7,8].
Other important functions of the purine nucleotide cycle
are the deamination of amino acids and the regulation of
the glycolytic pathway by the formation of ammonia and
IMP [7-9].
It has been shown that physical activity lowers skeletal
muscle AMPD activity. Furthermore, AMPD expressionntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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ition [5,7-9]. In a sprint training study, a decrease in
AMPD activity was reported concurrent with an increase
in the proportion of fast-twitch (type II) fibres. There-
fore, AMPD expression appears to be influenced by
the intensity of physical activity [10-12]. The muscle-
specific isoform of AMPD (adenosine monophosphate
deaminase-1 (AMPD1), also known as myoadenylate
deaminase) predominates in all skeletal muscle fibres.
The gene encoding this isoform (AMPD1) is located on
chromosome 1 (1p13). AMPD1 is mainly expressed in
fast-twitch (type II) muscle fibres. Differential AMPD1
gene expression may contribute to quantitative variations
in enzyme activity across muscle groups with different
types of fibres [8-10]. The nonsense mutation c.34C > T
(C to T transition in nucleotide 34, p.Gln12X, rs17602729)
in exon 2 of the AMPD1 gene converts glutamine codon
(CAA) into the premature stop codon (TAA), which re-
sults in the early interruption of protein synthesis and ap-
pears to be the main cause of AMPD deficiency [1-14].
According to the 1000 Genomes project, the polymorph-
ism of the AMPD1 was found at a frequency of 11% in
European Caucasians (11% in Finland, 14% in England
and Spain, and 8% in Italy), 1% in Africans, and 8% in
Americans surveyed but was not present in any Asian
populations (http://www.1000genomes.org/).
Studies have shown, part of the population who ex-
press the mutant AMPD1 T allele (2% of the Caucasian
population are homozygous [TT genotype] and approxi-
mately 20% are heterozygous [CT genotype]) are vulner-
able to muscular cramps, pain, and premature fatigue
during exercises [4,11,15,16]. Tarnopolsky et al. [17] sug-
gested that the mutation of the AMPD1 might be a
harmless genetic variant [17]. Individuals with AMPD1
deficiency (TT genotype) have extremely low skeletal
muscle AMPD activity, heterozygous (CT genotype) in-
dividuals have intermediate AMPD activity, and homo-
zygous individuals with normal AMPD1 alleles (CC
genotype) have high AMPD activity [9,10]. Moreover,
force-generating capacity during repetitive submaximal
isometric muscle contractions was shown to be reduced
in subjects with AMPD1 deficiency compared with sed-
entary controls [6]. Colombini et al. [18] have found that
in elite endurance athletes the frequency of the AMPD1
mutant T allele is lower than in controls from the general
population [18]. However since no differences in indica-
tors of endurance performance were found between ath-
letes with different genotypes, it was concluded that the
AMPD1 C34T variation does not significantly impair en-
durance performance [5,18]. Furthermore, two studies
reported low frequency of the T allele in a group of top-
level Spanish male endurance athletes [5] and Polish
rowers [13] compared with controls. Several studies have
shown that power-oriented athletes have a significantlylower frequency of the AMPD1 T allele than controls
[7,14]. Varying findings reported by different groups of
researchers show that at this point there is no consensus
on the actual effect of AMPD1 polymorphisms on ath-
letic performance.
Therefore the purpose of the present study was two-
fold. First, we determined the frequency distribution of
the AMPD1 C34T alleles and genotypes in a group of
Elite Lithuanian athletes. This group was compared with
randomly selected healthy Lithuanian non-athletes. The
second aim of this study was to compare common an-
thropometric measurements and laboratory indexes of
muscle strength and endurance performance between the
groups of athletes depending on their AMPD1 genotype.
Results
The distribution of AMPD1 C34T polymorphism geno-
type and allele frequencies in 204 Lithuanian athletes
was compared to 260 healthy untrained individuals. Data
of genotype and allele distribution analysis is presented
in Table 1.
Results showed that the AMPD1 C34T genotype distri-
bution was in line with Hardy-Weinberg equilibrium
within all groups (P > 0.05). AMPD1 genotype frequen-
cies were significantly different between the total athlete
group (74.2% CC; 24.9% CT; 0% TT) and the control
group (72.2% CC; 25.5% CT; 2.4% TT; P = 0.025)
(Table 1). The frequency of homozygous TT genotypes
was 2.4% in the control group. The TT genotype was
completely absent in the athlete group. There was a sig-
nificantly lower frequency of the T allele in the sprint/
power-orientated athletes (4.3%) compared with the
mixed athletes (16.4%) and controls (16.0%). There were
significantly more sprint/power-orientated athletes with
the AMPD1 CC genotype (86.3%) compared with the en-
durance athletes (72.9%), mixed athletes (67.1%), and
controls (74.2%) (Table 1). Analysis of the distribution of
AMPD1 alleles between genders in the athlete and con-
trol groups revealed no significant differences.
Since the AMPD1 TT genotype was completely absent
in the athlete group, only CT and CC genotypes were
used for further analysis. The phenotypical variables of
the control group were not measured due to various
limitations. The differences between the mean values of
the phenotypical variables were analysed with respect to
gender and sports groups.
Irrespective of the AMPD1 genotype, the mean values
of anaerobic power parameters — anaerobic alactic mus-
cular power (AAMP), right and left hand grip strength
(LGS and RGS) — were significantly higher for males
compare to females (P < 0.01) (Table 2). Males carriers
of the AMPD1 CC genotype had significantly lower fat
mass than female athletes. Other important anthropo-
metric variables including height, weight, body mass index
Table 1 Frequency distribution of the C34T AMPD1 alleles and genotypes
Individuals Group
size (n)
Allele frequencies (%) p-value compared
with control
AMPD1 C34T genotype frequencies (%) P-value
HWE
P-value compared
with controlC T CC CT TT
Endurance group 84 86.9 13.1 0.603 62 (72.9)* 22 (25.9)* 0* 0.167 0.359
Sprint and power
group
47 95.7♦ 4.3♦ 0.039 43 (86.3)*♣ 4 (11.8)*♣ 0*♣ 0.761 0.010
Mixed group 73 83.6♦ 16.4♦ 0.999 49 (67.1) 24 (32.9)♣ 0♣ 0.092 0.216
Total athletes 204 87.7 12.3 0.287 154 (74.2) 50 (24.9) 0 0.050 0.025
Control subjects 260 84.0 16.0 - 185 (72.2) 67 (25.5) 8 (2.4) 0.525 -
*χ2 = 5.62, d.f. = 2, P = 0.021 for AMPD1 genotype frequencies in endurance athletes versus sprint/power athletes.
♣χ2 = 9.09, d.f. = 2, P = 0.002 for AMPD1 genotype frequencies in sprint/power athletes versus mixed athletes.
♦χ2 = 6.32; df = 1; P = 0.004 for AMPD1 alleles frequencies in sprint/power athletes versus mixed athletes.
Significant mean differences (P < 0.05) are in bold.
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term explosive muscle power (STEMP), and aerobic
parameter maximum oxygen uptake (VO2max) were
significantly higher in the male CC genotype athletes
(P < 0.02). The latter results confirm a physiological gen-
der difference between phenotypic values. Therefore, as
the next step, we compared male and female differences
between the AMPD1 CC and CT genotypes separately.
The only significant statistical difference was obtained for
STEMP in the subgroup of male athletes. Males carriers of
the AMPD1 CC genotype had higher STEMP compared
to the CT genotype male athletes (2010.4 ± 486.2W vs.
1790.2 ± 489.4W; P = 0.018).
ANOVA results revealed that irrespective of the
AMPD1 genotype, the sprint/power group athletes had
on average higher muscle mass, handgrip strength,
STEMP, and AAMP than the mixed group (P < 0.006)
(Table 3). Average muscle mass, handgrip strength, and
AAMP values were also significantly different between
the endurance athletes and the mixed group (P < 0.0001)
irrespective of the genotype. For the AMPD1 CC geno-
type athletes, average STEMP value of the sprint/power
group was significantly higher than the endurance group
(P < 0.0001), while for the CT genotype average STEMP
value of the endurance group was significantly higher
than the mixed group (P < 0.0001) (Table 3). Comparison
of the phenotypic characteristics of the sports groups,
specifically the AMPD1 CC and CT genotype athletes,
revealed that sprint/power athletes carrying the CC
genotype had significantly lower handgrip strength com-
pared with CT genotype athletes (P < 0.05), and mixed
athletes carrying the AMPD1 CC genotype had higher
handgrip strength and STEMP compared with the CT
genotype athletes (P < 0.03).
We estimated post hoc the statistical power of the Chi-
square and ANOVA tests employed in our study by
G*power software. We used medium effect size recom-
mended in G*power program and the significance level
alpha = 0.05.Given medium effect size w = 0.3, the power calculation
of Chi-square tests for differences in allele frequencies be-
tween the athletes and the controls yielded: power = 1.00
for total sample size n = 464 (204 athletes + 260 controls).
The empirical power of the Chi-square tests for differ-
ences between the allele frequencies in different sport
groups was equal to 0.98 and respectively for genotype
differences - 0.95.
The empirical power of the ANOVA test for the mean
differences of Lithuanian athletes’ phenotypic indexes
between three different sport groups for the medium ef-
fect size f = 0.25 and the total number of athletes with
AMPD1 CC genotype (n = 154) calculated by G*power
was 0.79. The empirical power for AMPD1 CT genotype
group (n = 50) is low and equal to 0.32.
We used G*power to estimate the empirical effect size
of the ANOVA test for all phenotypic variables between
sports groups separately for AMPD1 CC and CT geno-
types. For AMPD1 CC and CT genotypes, average empir-
ical effect size was 0.37 and 0.71 respectively. Assuming
the empirical effect size as true one, with alpha = 0.05, we
obtain that the empirical power is higher than 0.84 and
sample size is sufficient to detect large effect size for almost
all phenotypic variables except VO2max (for CC and CT
genotypes), fat mass (CC genotype), height (CT genotype).
In order to achieve the power of 0.8 for the latter variables,
the sample size should be larger as 1000 which is beyond
the possibilities of Lithuanian athletes’ population.
Discussion
Elite athletic status is a polygenic trait with multiple can-
didate gene variants playing a certain role, either alone
or through complex, gene-gene and gene-environment
interactions. In the present study, we investigated the asso-
ciation between AMPD C34T polymorphism (rs17602729)
and athletic performance in elite Lithuanian athletes
group. We chose the AMPD1 C34T polymorphism
due to possible associations with the various aspects
of muscle function and capacity that were reported in
Table 2 Descriptive summary of phenotypic characteristics of athletes with respect to gender and athlete genotypes
Phenotype Gender AMPD1 CC genotype AMPD1 CT genotype p-value between
genotypen Mean SD p-value n Mean SD p-value
Height (cm) Total 154 178.3 9.5 50 176.2 9.3
Male 123 179.9 9.3 0.000 37 177.3 9.7 0.164 0.146
Female 31 172.2 7.3 13 173.1 7.7 0.736
Weight (kg) Total 154 73.2 13.4 50 69.4 13.6
Male 123 75.4 13.5 0.000 37 71.4 14.3 0.082 0.127
Female 31 64.5 8.6 13 63.8 9.8 0.810
BMI (kg/m2) Total 154 22.74 2.84 50 22.04 3.15
Male 123 23.06 3.00 0.000 37 22.36 3.45 0.115 0.231
Female 31 21.47 1.56 13 21.12 1.87 0.526
RGS (kg) Total 154 46.9 9.6 50 44.9 12.1
Male 123 49.5 8.4 0.000 37 48.0 11.4 0.002 0.469
Female 31 36.6 6.8 13 36.2 9.7 0.891
LGS (kg) Total 154 46.0 9.8 50 42.7 11.5
Male 123 48.4 8.7 0.000 37 45.3 11.1 0.005 0.079
Female 31 36.3 8.0 13 35.2 9.6 0.687
Fat mass (kg) Total 154 7.98 2.41 50 8.15 2.70
Male 123 7.65 2.02 0.010 37 7.28 2.01 0.000 0.330
Female 31 9.32 3.26 13 10.62 2.97 0.224
Muscle mass (kg) Total 154 39.1 8.9 50 36.6 8.8
Male 123 40.6 8.5 0.000 37 37.7 9.5 0.055 0.072
Female 31 33.0 7.6 13 33.4 5.3 0.870
STEMP (W) Total 154 1943.0 486.2 50 1771.8 447.0
Male 123 2010.4 489.9 0.001 37 1790.2 489.4 0.628 0.018
Female 31 1675.6 370.1 13 1719.3 305.4 0.710
AAMP (W) Total 154 1204.1 219.3 50 1164.1 218.3
Male 123 1253.7 205.5 0.000 37 1216.1 225.9 0.000 0.342
Female 31 1007.5 153.3 13 1016.0 97.1 0.854
VO2max (ml/kg/min) Total 154 61.6 6.0 50 59.8 6.2
Male 123 62.2 5.9 0.019 37 60.3 6.1 0.321 0.085
Female 31 59.4 6.2 13 58.3 6.4 0.603
BMI = body mass index. RGS and LGS = right and left hand grip strength. STEMP = short-term explosive muscle power. AARG = anaerobic alactic muscular power.
VO2max = maximum oxygen uptake.
Significant mean differences (p < 0.05) between gender groups are in bold.
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that this gene variation has an impact on human physical
characteristics [1,5,7,12].
The main findings of the present study were: (i) a
significantly lower frequency of the AMPD1 T allele
among the investigated group of elite Lithuanian sprint/
power athletes compared to sedentary controls; and
(ii) the AMPD1 CC genotype is associated with anaer-
obic muscle performance (Vertical Jump). These results
are in accordance with previous studies showing that C
allele of the AMPD1 gene is associated with anaerobic
performance [5,7,8,12].The C34T polymorphism in the AMPD1 gene encoding
for the skeletal muscle-specific isoform of AMP deaminase
(AMPD1) is a common variation among Caucasians that
can impair exercise capacity [3]. Approximately 2% of the
general Caucasian population who are homozygous for
AMPD1 rare T alleles (TT genotype) exhibit a skeletal
muscle AMPD1 deficiency [7,9].
Results of this study show that the frequency of TT
homozygotes in the control group was 2.4%, but none
were found among the athletes. We determined the fre-
quency of the T allele to be 16.0% in the control group
(in line with other European Caucasian populations) and
Table 3 Descriptive summary of phenotypic characteristics of athletes with respect to sport groups and athlete genotypes
Phenotype Group AMPD1 CC genotype AMPD1 CT genotype p-value between
genotypen Mean SD p-value n Mean SD p-value
Height (cm) Endurance (1) 62 181.4 9.0 p12 = 0.157 22 179.1 8.6 p12 = 1.000 0.308
Power (2) 43 177.8 10.0 p23 = 0.369 4 179.0 9.3 p23 = 0.678 0.826
MIX (3) 49 174.9 8.3 p31 = 0.001 24 173.0 9.3 p31 = 0.080 0.393
Weight (kg) Endurance (1) 62 75.3 13.2 p12 = 1.000 22 72.9 12.1 p12 = 0.027 0.446
Power (2) 43 77.7 14.3 p23 = 0.000 4 89.9 4.9 p23 = 0.000 0.100
MIX (3) 49 66.5 10.0 p31 = 0.001 24 62.9 11.4 p31 = 0.014 0.171
BMI. (kg/m2) Endurance (1) 62 22.66 2.34 p12 = 0.003 22 22.60 2.32 p12 = 0.000 0.925
Power (2) 43 24.40 3.37 p23 = 0.000 4 28.20 2.00 p23 = 0.000 0.032
MIX (3) 49 21.40 2.14 p31 = 0.037 24 20.50 2.50 p31 = 0.013 0.115
RGS (kg) Endurance (1) 62 47.0 9.9 p12 = 0.051 22 49.6 8.6 p12 = 0.023 0.272
Power (2) 43 51.3 8.9 p23 = 0.000 4 63.5 6.6 p23 = 0.000 0.011
MIX (3) 49 42.8 8.1 p31 = 0.049 24 37.5 10.0 p31 = 0.000 0.018
LGS (kg) Endurance (1) 62 46.8 9.5 p12 = 0.202 22 46.8 7.3 p12 = 0.010 0.990
Power (2) 43 50.2 9.0 p23 = 0.000 4 61.5 8.4 p23 = 0.000 0.020
MIX (3) 49 41.2 9.1 p31 = 0.006 24 35.8 9.9 p31 = 0.000 0.021
Fat mass (kg) Endurance (1) 62 8.12 2.28 p12 = 1.000 22 7.65 1.68 p12 = 0.035 0.370
Power (2) 43 7.94 2.51 p23 = 1.000 4 11.33 1.91 p23 = 0.071 0.012
MIX (3) 49 7.84 2.51 p31 = 1.000 24 8.08 3.24 p31 = 1.000 0.740
Muscle mass (kg) Endurance (1) 62 40.3 9.4 p12 = 0.246 22 39.7 7.4 p12 = 0.020 0.785
Power (2) 43 43.2 8.7 p23 = 0.000 4 50.2 3.3 p23 = 0.000 0.119
MIX (3) 49 34.1 5.6 p31 = 0.000 24 31.4 6.5 p31 = 0.000 0.077
STEMP (W) Endurance (1) 62 1786.6 444.0 p12 = 0.000 22 1918.2 399.2 p12 = 0.080 0.224
Power (2) 43 2405.9 347.8 p23 = 0.000 4 2380.5 310.2 p23 = 0.000 0.889
MIX (3) 49 1734.8 359.5 p31 = 1.000 24 1536.1 353.1 p31 = 0.003 0.029
AAMP (W) Endurance (1) 62 1224.1 248.3 p12 = 0.603 22 1258.9 191.8 p12 = 1.000 0.503
Power (2) 43 1277.8 186.5 p23 = 0.001 4 1339.0 339.2 p23 = 0.020 0.562
MIX (3) 49 1114.3 175.8 p31 = 0.022 24 1048.0 158.0 p31 = 0.001 0.122
VO2max (ml/kg/min) Endurance (1) 62 62.3 5.4 p12 = 1.000 22 61.3 4.0 p12 = 1.000 0.372
Power (2) 43 62.1 6.3 p23 = 0.567 4 58.4 2.9 p23 = 1.000 0.250
MIX (3) 49 60.4 6.5 p31 = 0.298 24 58.6 7.8 p31 = 0.409 0.293
BMI = body mass index. RGS and LGS = right and left hand grip strength. STEMP = short-term explosive muscle power. AARG = anaerobic alactic muscular power.
VO2max = maximum oxygen uptake.
For each phenotypic characteristic, we report p-values between 12, 23 and 31 groups respectively as indicated in the second column of the table. P-values
adjusted for multiple comparisons using the Bonferroni test.
Significant mean differences (p < 0.05) between sports groups and genotype are in bold.
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were significantly more sprint/power athletes with the
AMPD1 CC genotype (86.3%) compared with the endur-
ance athletes (72.9%), mixed athletes (67.1%), and controls
(74.2%) (P < 0.025). These results support the association
of the C allele with sprint/power performance. Our data on
the predominance of the AMPD1 C allele and CC geno-
type in sprint/power athletes was in line with the results of
other studies on the association of AMPD1 C34T and an-
aerobic muscle performance [5,7,8].Cieszczyk et al. [14] and Fedotovskaya et al. [7] dem-
onstrated that power-oriented athletes had a signifi-
cantly lower frequency of the AMPD1 T allele than the
controls [5,12].
The potential favourable effect of the AMPD1 wild-
type alleles (CC genotype carriers) on elite sprint power
athletic status was additionally supported by the finding
that the sprint/power elite athletes with AMPD1 CC
genotype achieved better results in nearly all sprint and
power measurements. However, it must be emphasized
Ginevičienė et al. BMC Genetics 2014, 15:58 Page 6 of 9
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for this striking finding are unclear. We consider that
the results of our study are overall sound, as all of the
following criteria were met the primary validity criteria
for association study [19]: cases (athletes) clearly presented
the main study phenotype (i.e. being an elite athlete); gen-
etic assessment were accurate and unbiased; participants
within groups were ethnically-matched; and genotype dis-
tributions were in HWE in the control (general Lithuanian
population) and athletes' groups.
Our study has limitations. Our group of elite athletes
was somewhat small, especially after the stratification
according to the sports’ category. However considering
that there is a limited number of elite athletes in
Lithuania, we were unable to recruit additional individuals
for this study.
We investigated phenotypes that are related to phys-
ical performance to begin creating a chain of evidence
linking AMPD1 C34T to success in sports. Because the
AMPD1 TT genotype was absent in the group of ath-
letes, only CT (n = 50) and CC (n = 154) genotyped ath-
letes were used for the analysis. Aerobic capacity was
determined using maximum oxygen uptake (VO2max),
which is widely accepted as the single best measure of
cardiovascular fitness and maximal aerobic power. In-
stantaneous or explosive power in the lower extremities
was measured by a vertical jump test and stair-climbing
test (short-term power is the work performed over a
brief period of time using maximal effort). Maximal iso-
metric power of the forearm muscles was measured
using handgrip strength. These are very rapid move-
ments that are dependent on anaerobic energy use in
the muscles and primarily reliant on creatine phosphate.
Strength and anaerobic power tests are performance
tests most indicative of muscle properties and have been
proved to have a significant genetic component [20].
The AMPD1 skeletal enzyme is a very important regulator
of muscle energy metabolism during exercise. AMPD1 is
activated during short-term, high-intensity exercise, when
the rate of ATP use exceeds the cell’s potential to resyn-
thesize it [13]. Previous studies have shown that individ-
uals with the AMPD1 TT genotype exhibit low AMPD1
activity and a faster accumulation of blood lactate during
early recovery from a 30-s sprint exercise [8,9]. Fischer
et al. [9] revealed a faster power decrease in TT genotype
carriers during the 30-s Wingate cycling test [7]. In a
study done by Rico-Sanz et al. [6], individuals with the
AMPD1 TT genotype had diminished exercise capacity
and cardiorespiratory responses to exercise in a sedentary
state. Furthermore, the training response of ventilatory
phenotypes during maximal exercise was lower in AMPD1
TT genotype carriers [4].
Our results demonstrated that the sprint/power ath-
letes with AMPD1 wild-type alleles (CC genotype carriers)achieved better results in nearly all sprint and power
measurements. AMPD1 CC genotyped athletes’ from the
sprint/power group had an average STEMP value (based
on the vertical jump test) significantly higher than endur-
ance group athletes with the same genotype (P < 0.05).
Interestingly, we found that athletes in the mixed group
(utilising mixed anaerobic and aerobic energy production)
carrying the AMPD1 CC genotype had higher handgrip
strength and STEMP than the CT genotype athletes in the
same group (P < 0.05).
Our results confirm physiological gender-dependant
differences between phenotypic values. AMPD1 wild-
type C allele homozygous males had higher STEMP than
the CT genotype male athletes (P < 0.05). Indeed, gender
is another factor affecting skeletal muscle AMPD1 activity.
Norman (1998) revealed that on average 14–18% higher
AMPD1 activities are found in the skeletal muscle of males
compared with females [6]. This is similar to what has been
observed for other enzymes such as lactate dehydrogenase
and phosphofructokinase and suggests a coupling between
AMPD1 activity and glycolytic capacity of human skeletal
muscles [6]. Our study has confirmed this observation. A
statistically significant difference was obtained for the an-
aerobic STEMP test in the subgroup of CC-genotyped
male athletes.
Based on this information, it would appear that the
AMPD1 C allele is favourable for sprint/power perform-
ance. This finding is consistent with previous studies that
have reported association between the AMPD1 C allele
and status of sprint/power athletes [5,7,8,12].
Our results demonstrated no association for the
AMPD1 C34T polymorphism and aerobic performance
phenotype (VO2max). Although the latter partly are not
significant due to limited sample size, there are other
studies those support the same findings. Rico-Sanz et al.
found no significant differences between AMPD1 CC
and CT genotype athletes in the VO2max values attained
by previously sedentary individuals [4].
The results of this study indicate that the effect of the
C34T variation of the AMPD1 gene is essential during
intense exercise. Our data indicates that the presence of
the AMPD1 C allele, in conjunction with other environ-
mental and genetic factors, predicts anaerobic capacity.
Conclusions
Our data suggest that the AMPD1 C allele may help
athletes to attain elite status in sprint/power-oriented
sports. Differences in the distribution of AMPD1 C34T
genotypes in the athletes examined and controls and a
lower frequency of allele T in sprint/power athletes sug-
gest that allele T is a factor unfavourable for athletics in
sprint/power-oriented sports categories. The results in-
dicate the relationship between the AMPD1 gene C34T
variation and muscular activity in an anaerobic mode in
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one of the markers associated with the performance of
sprint and power.
The results provide novel information about the
AMPD1 molecular mechanisms behind physical per-
formance. However, it should be noted that these find-
ings need to be replicated in larger cohorts to confirm
the associations. In addition, new physiological and
molecular mechanisms behind adaptations to exercise
training may be found by studying the genes affecting
physical performance. It is important to clarify that al-
though the AMPD1 gene and the polymorphisms within
this gene are important for physical capacity phenotypes,
they are not products of a single gene exclusively, be-
cause they also heavily depend on composition of muscle
fibre, training status, gender, and other environmental
and genetic factors.
Methods
The Lithuanian Bioethics Committee approved the study
and written informed consent was obtained from each
participant.
Participants
The study involved 204 athletes (aged 22.0 ± 6.3 years) and
260 controls (healthy unrelated individuals [aged 36.2 ± 7.2
years] from six ethno-linguistic Lithuanian groups). The
athletes and control groups were all Caucasians. The
204 elite athletes studied (160 male and 44 female) con-
sisted of Olympic candidates and athletes who had par-
ticipated in international competitions and had no less
than 7 years of experience in their sports categories.
The athletes were stratified into three groups according
to the duration and distance of the event, in sports dis-
ciplines that ranged from endurance-oriented to power-
oriented sports. The endurance group (n = 84) included
very long (race duration >30 min), long (race duration
5–30 min), and medium (race duration 45 s to 5 min)
distance athletes: skiers, road cyclists, biathletes, long-
distance runners, modern pentathletes, swimmers, and
rowers. The sprint/power group (n = 47) included sprinters
and other power athletes with predominantly anaerobic
energy production: sprinters, jumpers and throwers. The
mixed group (n = 73) comprised athletes whose sports uti-
lized mixed anaerobic and aerobic energy production:
wrestlers, tennis players, handball players, and footballers.
Anthropometric measurements
Body height was measured to the nearest 0.01 m with
the subject standing with their back to a wall-mounted
stadiometer. Weight was measured to the nearest 0.1 kg
with calibrated scales. Body mass index (BMI; in kg/m2)
was calculated. Highly trained athletes may have a
high BMI because of increased muscularity rather thanincreased body fat. Total body fat mass (FM, in kg) was
determined by measuring the size of the thickest regions
of the forearm, humeral area, thigh, and calf and by using
a calliper to measure the thickness of the skin, thus deter-
mining the amount of subcutaneous fat [21].
Muscle strength measurements
Anaerobic power was determined with three different
tests using the technique recommended by Brown and
Weir [21]. Short-term explosive muscle power (STEMP,
vertical jump test, in W) was measured by asking the
subject to perform a maximal vertical jump (on a contact
platform), and the power output expressed per unit of
body weight was measured according to Bosco proce-
dures and modifications by Linthorne [22]. Anaerobic
alactic muscular power (AAMP, in W) was estimated by
a stair-climbing test proposed by Margaria [23-25]. Max-
imal isometric power of the forearm muscles (handgrip
test) was measured according to the procedures de-
scribed by Mathiowetz et al., with an adjustable mechanical
hand dynamometer and expressed in kilograms (kg). For
convenience, we denote left and right hand grip strength
as LGS and RGS respectively [21,26].
Measurements of endurance performance
Aerobic capacity was determined by using maximum
oxygen consumption (VO2max). VO2max refers to the
maximum amount of oxygen that an individual can util-
ise during maximal or exhaustive exercise. It is measured
as millilitres of oxygen used in 1 minute per kilogram of
body weight (ml/kg/min). The gas exchange was measured
using a facemask apparatus attached to a continuous,
breath-by-breath monitoring system (Oxycon Mobile,
Germany). The athletes were evaluated while pedalling on
a cycle ergometer (Ergoselect 100 P, Germany) or running
on a treadmill (Cosmos Mercury, Germany) according to
an incremental procedure until exhaustion. Oxygen uptake,
pulmonary ventilation, ventilatory equivalents for oxygen
and carbon dioxide, and end-tidal partial pressure of oxy-
gen and carbon dioxide were measured during each test.
All assessments were carried out by trained individuals
according to a standardised procedure. Each participant
was given two attempts (before and after the preparation
period for the most important competitions) and the
best attempts were used in the analyses.
Genotyping
Genomic DNA was extracted from peripheral blood leu-
kocytes by the standard phenol-chloroform extraction
method. Genotyping of the AMPD1 (rs17602729) poly-
morphism was performed using polymerase chain reac-
tion (PCR). The resulting PCR products were genotyped
by restriction fragment length polymorphism analysis.
The AMPD1 polymorphism was amplified using PCR
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verse, 5'-GAATCCAGAAAAGCCATGAGC-3' primers
as recommended by Norman et al. [8]. The amplified
fragment subsequently underwent digestion by NspI
endonuclease (Thermo Scientific Fermentas, Lithuania).
Digested PCR fragments (216 bp fragments for C allele
and 194 bp with 22 bp for T allele) were separated by
2% agarose gel electrophoresis, stained with ethidium
bromide, and viewed in UV light.
Data analysis
Deviation from the Hardy-Weinberg equilibrium was
statistically evaluated. Distribution differences between
allele and genotype frequencies were tested using chi-
square or Fisher’s exact tests. The average differences for
each genotype of Lithuanian athletes’ phenotypic indexes
were evaluated by using Student’s t-test or one-way dis-
persion analysis (ANOVA). The post-hoc Bonferroni test
was applied for multiple comparisons between groups.
All phenotypic values (quantitative variables) are pre-
sented as the mean ± standard deviation (SD). P-values
less than 0.05 were considered statistically significant.
The IBM SPSS (v.21) statistical software package was
used to obtain the results. We estimated post hoc power
of the Chi-square and ANOVA tests assuming medium
effect size by G*power software [27].
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